NEW YORK, NY--(Marketwired - June 12, 2015) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE).
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that (1) the STEP Study was conducted by a clinical research organization which lacked autonomy; and (2) the trial drug supply for the STEP Study was shipped to clinical sites at lower temperatures than were permitted by the drug's specifications. As a result, the Company announced on August 21, 2014, that data and other results from the clinical research would be delayed.
After the announcement, the Company's share price declined from a closing price of $7.54 on August 20, 2014, to a closing price of $5.66, or more than 24.9%, on August 21, 2014.
Furthermore, on April 20, 2015, Ampio announced that "the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control test." On this news, shares of Ampio fell $5.18 per share, to close at $2.69, or more than 65.8%, on April 24, 2015.
Request more information now by clicking here: www.faruqilaw.com/AMPE. There is no cost or obligation to you.
Take Action
If you invested in Ampio stock or options between January 13, 2014 through April 24, 2015 and would like to discuss your legal rights, visit www.faruqilaw.com/AMPE. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Ampio's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.